Tobacco.org

Corixa Partners With Japan Tobacco To Research Lung Cancer Vaccines in Japan and North America 

Corixa Corporation (Nasdaq: CRXA), a research- and development-based biotechnology company, today announced it has entered into a multi-year research collaboration and license agreement with the pharmaceutical division of Japan Tobacco Inc. (JT) to support Corixa's development of therapeutic lung cancer vaccines. The agreement provides JT with exclusive rights to vaccine and antibody-based products aimed at treating lung cancer and potentially other solid tumors in humans, principally in Japan and North America, as well as co-exclusive rights, with Zambon Group spa, in China.

Jump to full article »